Please select the option that best describes you:

When do you offer PMRT for clinical T3N0 breast cancer with a pCR after neoadjuvant chemotherapy?  

Would extensive residual DCIS (>5cm), hormone receptor negativity, Her2+ status, or age < 40 effect your decision?



Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more